Sources
Loading...
Additional media
Loading...
DeepNewz, mobile.
People-sourced. AI-powered. Unbiased News.
On November 18, 2024, the U.S. Supreme Court did not grant review in any new cases, as confirmed by multiple sources. The Court declined to review a Fourth Circuit ruling that paused West Virginia's law prohibiting transgender students from participating in sports teams aligned with their gender identity. Additionally, the Court turned away an appeal from Norwich Pharmaceuticals, a subsidiary of Alvogen, seeking to sell a generic version of Bausch Health's diarrhea medication, Xifaxan. Furthermore, the Supreme Court declined to hear an antitrust lawsuit involving 17 U.S. states against Google, thereby upholding a ruling that requires a South Carolina agency to release records sought by the tech giant for its defense.
SCOTUS declined to hear an appeal in an antitrust lawsuit by 17 US states against Google, leaving in place a ruling that a South Carolina agency must release records the Alphabet unit is seeking for its defense https://t.co/RaKTIrQQW1 @MikeScarcella https://t.co/pejnVOPLsW
SCOTUS turned away a bid by Alvogen's subsidiary Norwich Pharmaceuticals to sell a generic version of Canada-based Bausch Health's blockbuster diarrhea drug Xifaxan https://t.co/nIdO2REn4H https://t.co/w8WM8mmo5y
JUST IN: The Supreme Court doesn't grant review in any new cases, and declines to review a 4th Circ. ruling that paused West Virginia's law barring transgender students from competing on sports teams consistent with their gender identity. #SCOTUS https://t.co/uDDbHk07E1
